Safyral:News and Information

Ranked #24,902 in Healthy Living, #353,020 overall | Donates to Blue Mountain Wildlife

Bayer's SAFYRAL oral contraceptive receives FDA approval

The U.S. Food and Drug Administration (FDA) has approved a new oral contraceptive,(OC), Safyral (drospirenone 3 mg/ ethinyl estradiol 30 mcg/ levomefolate calcium 451 mcg tablets and levomefolate calcium 451 mcg tablets). In women who choose an OC for birth control, Safyral raises folate levels for the purpose of reducing the risk of rare neural tube defects (NTDs) in a pregnancy conceived while taking Safyral or shortly after discontinuing it. Safyral provides the birth control Yasmin (drospirenone 3 mg/ ethinyl estradiol 30 mcg) with 451 mcg levomefolate calcium, which is a B vitamin.

Bayer's second oral contraceptive containing folate.

SAFYRAL is the second Bayer OC which contains folate. In September, the FDA approved Beyaz, the first OC approved by the FDA to raise folate levels in women who choose an OC for birth control.

Women of childbearing age are advised by the CDC and other groups to supplement their diet with at least 400 mcg of folic acid daily to prevent neural tube defects, which occur during the first weeks of gestation. Adding folate to the OC raises folate levels in women who conceive while on the new pill or shortly after discontinuing it.

The progestin drospirenone may increase potassium. You should not take Safyral if you have kidney, liver or adrenal disease because this could cause serious heart and health problems. Other drugs may also increase potassium. and during the first month that you take Safyral, you should have a blood test to check your potassium level.

.

New Amazon

Loading

New Guestbook

Text module

by

tjlpa

I am an attorney based in Wilmington, North Carolina. I work for people around the country who have been seriously injured by their use of unsafe prescription... more »

Feeling creative? Create a Lens!